Oaktree Acquisition Corp. III Life Sciences (OACC) Liabilities and Shareholders Equity (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences (OACC) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $204.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 3.85% year-over-year to $204.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $808.4 million (changed N/A YoY) and the FY2025 annual result came in at $203.1 million, up 4.03% from the prior year.
• Liabilities and Shareholders Equity advanced to $204.8 million in Q1 2026, from $203.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $204.8 million in Q1 2026 to a low of $195.3 million in Q4 2024.
• A 3-year average of $200.1 million and a median of $200.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity gained 4.03% — and 2026, when it climbed 3.85%.
• Tracing OACC's Liabilities and Shareholders Equity over 3 years: stood at $195.3 million in 2024, then climbed by 4.03% to $203.1 million in 2025, then advanced by 0.85% to $204.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $204.8 million (Q1 2026), $203.1 million (Q4 2025), and $201.2 million (Q3 2025), per Business Quant data.